中国埃克替尼治疗非小细胞肺癌专家共识(2015版)

China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version) Yuankai SHI, Yan SUN, Cuimin DING, Ziping WANG, Changli WANG, Zheng WANG, Chong BAI, Chunxue BAI, Jifeng FENG, Xiaoqing LIU, Fang LI, Yue YANG, Yongqian SHU, Milu WU, Jianxing HE, Yiping ZHANG, Shucai ZHANG, Gongyan CHEN, Honghe LUO, Rongcheng LUO, Caicun ZHOU, Yanbin ZHOU, Qingsong PANG, Hong ZHAO, Qiong ZHAO, Aiqin GU, Yang LING, Cheng HUANG, Baohui HAN, Shunchang JIAO, Hong JIAN Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, 100021 Beijing , China; Fourth Hospital of Hebei Medical University, 050000 Shijiazhuang, China; Tianjin Medical University Cancer Institute & Hospital, 300070 Tianjin, China; Shenzhen People's Hospital, 518020 Shenzhen, China; The Second Military Medical University Changhai Hospital, 200433 Shanghai, China; Fudan University Zhongshan Hospital, 200032 Shanghai, China; Jiangsu Cancer Hospital, 210009 Nanjing , China; The 307th Hospital of Chinese People’ s Liberation Army, 100071 Beijing , China; Chinese People’s Liberation Army General Hospital, 100853 Beijing , China; Beijing Cancer Hospital, 100142 Beijing , China; Jiangsu Province Hospital, 210029 Nanjing, China; Qinghai University Affiliated Hospital, 810000 Xining, China; The First Affiliated Hospital of Guangzhou Medical Unversity, 510000 Guangzhou, China; Zhejiang Cancer Hospital, 310022 Hangzhou, China; Beijing Chest Hospital, Capital Medical University, 101149 Beijing , China; Harbin Medical University Cancer Hospital, 150081 Harbin, China; The First Affiliated Hospital, Sun Yat-sen University, 510080 Guangzhou, China; Nanfang Medical University Nanfang Hospital, 510515 Guangzhou, China; Tongji University Affiliated Shanghai Pulmonary Hospital, 200433 Shanghai, China; The First Affiliated Hospital, Zhejiang University, 310003 Hangzhou, China; Shanghai Chest Hospital, Shanghai Jiaotong University, 200030 Shanghai, China; Changzhou Fourth People’s Hospital, 213001 Changzhou, China; Fujian Cancer Hospital, 350014 Fuzhou, China Corresponding author: Yuankai SHI, E-mail: syuankai@cicams.ac.cn DOI: 10.3779/j.issn.1009-3419.2015.07.01

[1]  Jie He,et al.  Annual report on status of cancer in China, 2011. , 2015, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[2]  B. Han,et al.  A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC). , 2014, Lung cancer.

[3]  S. Thongprasert,et al.  A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER) , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  Ying Cheng,et al.  Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. , 2013, The Lancet. Oncology.

[5]  Yi-long Wu,et al.  LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. , 2013 .

[6]  Ying Cheng,et al.  Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. , 2012, The Lancet. Oncology.

[7]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[8]  T. Ciuleanu,et al.  Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. , 2012, The Lancet. Oncology.

[9]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[10]  A. Gemma,et al.  F1000 highlights , 2010 .

[11]  G. Giaccone,et al.  Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. , 2010, The Lancet. Oncology.

[12]  S. Toyooka,et al.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.

[13]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[14]  Edward S. Kim,et al.  Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): Meta-analysis from four clinical trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Edward S. Kim,et al.  Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial , 2008, The Lancet.

[16]  T. Mok,et al.  Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  Kevin Carroll,et al.  Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.

[18]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.